Table 1 Randomized, double blind trials of topiramate for migraine prophylaxis
From: New drugs for migraine
Study | Target population | Topiramate N (dropouts) | Maintenance period (weeks) | Mean dosage/day (mg) | Migraine frequency (% reduction from baseline) | Therapeutic gain (% reduction vs.placebo) | Responders (Active %/Placebo %) | Adverse events (%) |
|---|---|---|---|---|---|---|---|---|
Storey [19] | MoAÂ +Â MA | 19 (3) | 8 | 125 | 36 | 24 | 26/10 | >68 |
Silvestrini [20] | Chronic migraine | 14 (1) | 8 | 50 | 61 | 60 | 71/7 | 36 |
Brandes [21] | MoA + MA | 120 (58) | 18 | 50 | 24 | 4 | 39/23 | >34 |
122 (57) | Â | 100 | 40 | 20 | 49/23 | >50 | ||
121 (47) | Â | 200 | 41 | 21 | 47/23 | >49 | ||
Diener [22] | MoA + MA | 139 (45) | 18 | 100 | 44 | 24 | 37/22 | >77 |
143 (78) | Â | 200 | 28 | 8 (NS) | 35/22 | >81 | ||
Silberstein [23] | MoA + MA | 117 (49) | 18 | 50 | 24 | 6 (NS) | 36/23 | >36 |
125 (42) | Â | 100 | 39 | 21 | 54/23 | >47 | ||
112 (67) | Â | 200 | 41 | 23 | 52/23 | >47 | ||
Silberstein [24] | MoA + MA | 138 (45) | 12 | 161 | 30 | 10 | 40/34 | 90 |
Silberstein [25] | Chronic migraine | 153 (73) | 12 | 86 | 37 | 9 | NA/NA | 83 |
Diener [142] | Chronic migraine | 32 (8) | 12 | 100 | 23 | 24 | 22/0 | 75 |
Keskinbora [27] | MoAÂ +Â MA | 20 (4) | 4 | 43 | 90 | NA | NA/NA | 40 |
Ashtari [28] | MoAÂ +Â MA | 31 (1) | 8 | 50 | 70 | NA | NA/NA | >23 |
Millan-Guerrero [29] | MoAÂ +Â MA | 45 (10) | 12 | 100 | 46 | NA | 60/NA | >47 |
Dodick [30] | MoAÂ +Â MA | 172 (70) | 22 | 91 | 41 | NA | 56/NA | 67 |